Cyprotex Expands its High Throughput Physicochemical Screening Facility
Our growing Physicochemical Screening group is moving to a dedicated facility within Alderley Park in the UK. We expect the state-of the art laboratory and office space to be operational in Q4 2021. Further expansion at Alderley Park is planned for 2022 and beyond!
Transcriptomics - The Future of Toxicology Prediction
Watch our latest webinar to find out about exciting new developments in the field of toxicology prediction and how transcriptomics can be used to predict drug-induced liver injury (DILI).
Presented by our in-house expert, Paul Walker PhD, the webinar covers our ground-breaking research building the largest transcriptomic database in the world and how this platform can be used to predict DILI risk with greatly enhanced accuracy compared with existing HCS-based DILI models.
Collaborative Research with Unilever Presented at WC11
Cyprotex is co-presenting with Unilever at the 11th World Congress on Alternatives and Animal Use in the Life Sciences 2021.
The Unilever-sponsored session, titled: "Assessing non-specific cellular stress responses for Chemical Safety Assessment" is presented by Cyprotex's Head of Toxicology, Paul Walker PhD, and Unilever's Science Leader, Paul Russell PhD.
The session highlights the benefits of working in partnership to develop new non-animal approaches and showcases the collaboration between Unilever and Cyprotex.
Using a high content multi-time point approach alongside analysis of calcium transients, the Cardiotox Screen panel assesses both structural and functional cardiotoxicity endpoints from a single cell population, and is able to accurately predict cardiotoxicity liabilities early in preclinical screening.